Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics

Neoplasia (United States)

Volumn 15, Issue 10, 2013, Pages 1138-1150

  Mattie, Mike ^a   Christensen, Ashley ^a   Chang, Mi Sook ^a   Yeh, William ^a   Said, Suzanne ^a   Shostak, Yuriy ^a   Capo, Linnette ^a   Verlinsky, Alla ^a   An, Zili ^a   Joseph, Ingrid ^a   Zhang, Yi ^a   Kumar Ganesan, Sathish ^a   Morrison, Karen ^a   Stover, David ^a   Challita Eid, Pia ^a  

^a Agensys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CHROMOSOME DELETION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; EXOME; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOUSE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR ENGRAFTMENT; TUMOR GENE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; DNA COPY NUMBER VARIATIONS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; MICE, SCID; MICRORNAS; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84887096419     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13922     Document Type: Article

References (51)

1. American Cancer Society (2013). American Cancer Society Facts and Figures 2013. American Cancer Society, Atlanta, GA.
2. Kindler HL (2007). Pancreatic cancer: an update. Curr Oncol Rep 9, 170-176.
3. Ellis LM and Fidler IJ (2010). Finding the tumor copycat. Therapy fails, patients don't. Nat Med 16, 974-975.
4. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, et al. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84, 1424-1431.
5. Voskoglou-Nomikos T, Pater JL, and Seymour L (2003). Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9, 4227-4239.
6. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, et al. (2009). A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 69, 3364-3373.
7. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, and Eckhardt SG (2012). Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9, 338-350.
8. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, et al. (2009). Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3, 469-482.
9. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, et al. (2011). A molecularly annotated platform of patientderived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1, 508-523.
10. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, et al. (2011). Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 17, 5793-5800.
11. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, Landron S, Bigot L, Nemati F, Cuilliere-Dartigues P, et al. (2012). Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18, 5314-5328.
12. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, et al. (2012). Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135, 415-432.
13. Mischek D, Steinborn R, Petznek H, Bichler C, Zatloukal K, Stürzl M, Günzburg WH, and Hohenadl C (2009). Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers. J Biomed Biotechnol 2009, 437284.
14. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, et al. (2012). Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 10, 125.
15. Pérez-Torras S, Vidal-Pla A, Miquel R, Almendro V, Fernández-Cruz L, Navarro S, Maurel J, Carbó N, Gascón P, and Mazo A (2011). Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Cell Oncol (Dordr) 34, 511-521.
16. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, et al. (2012). Molecular profiling of patientderived breast cancer xenografts. Breast Cancer Res 14, R11.
17. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12, 4652-4661.
18. Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, and Molina F (2010). Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 38, 6159-6175.
19. - - δCT method. Methods 25, 402-408.
20. Bianchi NO (2009). Y chromosome structural and functional changes in human malignant diseases. Mutat Res 682, 21-27.
21. Minner S, Kilgué A, Stahl P, Weikert S, Rink M, Dahlem R, Fisch M, Höppner W, Wagner W, Bokemeyer C, et al. (2010). Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology 42, 356-359.
22. Wallrapp C, Hähnel S, Boeck W, Soder A, Mincheva A, Lichter P, Leder G, Gansauge F, Sorio C, Scarpa A, et al. (2001). Loss of the Y chromosome is a frequent chromosomal imbalance in pancreatic cancer and allows differentiation to chronic pancreatitis. Int J Cancer 91, 340-344.
23. Harada T, Baril P, Gangeswaran R, Kelly G, Chelala C, Bhakta V, Caulee K, Mahon PC, and Lemoine NR (2007). Identification of genetic alterations in pancreatic cancer by the combined use of tissue microdissection and array-based comparative genomic hybridisation. Br J Cancer 96, 373-382.
24. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, Young BD, and Lemoine NR (2008). Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 27, 1951-1960.
25. Harada T, Chelala C, Crnogorac-Jurcevic T, and Lemoine NR (2009). Genomewide analysis of pancreatic cancer using microarray-based techniques. Pancreatology 9, 13-24.
26. Nowak NJ, Gaile D, Conroy JM, McQuaid D, Cowell J, Carter R, Goggins MG, Hruban RH, and Maitra A (2005). Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet 161, 36-50.
27. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al. (2009). DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27, 1806-1813.
28. Mahadevan D and Von Hoff DD (2007). Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6, 1186-1197.
29. Pilarsky C, Ammerpohl O, Sipos B, Dahl E, Hartmann A, Wellmann A, Braunschweig T, Löhr M, Jesenofsky R, Friess H, et al. (2008). Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med 12, 2823-2835.
30. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, and Watson PH (2011). Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 13, R126.
31. Ramaswamy S, Ross KN, Lander ES, and Golub TR (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet 33, 49-54.
32. Ali S, Saleh H, Sethi S, Sarkar FH, and Philip PA (2012). MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer 107, 1354-1360.
33. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, and Croce CM (2007). MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-1908.
34. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, and Oien KA (2012). MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18, 534-545.
35. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, and Schmittgen TD (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120, 1046-1054.
36. Mardin WA and Mees ST (2009). MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma? Ann Surg Oncol 16, 3183-3189.
37. Park JY, Helm J, Coppola D, Kim D, Malafa M, and Kim SJ (2011). MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol 17, 817-827.
38. Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wøjdemann M, and Johansen JS (2012). MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 25, 1609-1622.
39. Fu X, Guadagni F, and Hoffman RM (1992). A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 89, 5645-5649.
40. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, et al. (2012). Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One 7, e43192.
41. Campa D, Butterbach K, Slager SL, Skibola CF, de Sanjosé S, Benavente Y, Becker N, Foretova L, Maynadie M, Cocco P, et al. (2012). A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer 131, 803-812.
42. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, et al. (2006). Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98, 1739-1742.
43. Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, et al. (2012). Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 124, 575-581.
44. -/- (triple-knockout) and wild-type mice. Mol Cancer Ther 7, 2280-2287.
45. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, and Dees EC (2013). CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24, 1472-1478.
46. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Kim HT, and Lee JS (2008). Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59, 69-75.
47. Romero A, Martín M, Oliva B, de la Torre J, Furio V, de la Hoya M, García-Sáenz JA, Moreno A, Román JM, Diaz-Rubio E, et al. (2012). Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol 23, 1750-1756.
48. Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, et al. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 121, 628-637.
49. Barrett MT, Lenkiewicz E, Evers L, Holley T, Ruiz C, Bubendorf L, Sekulic A, Ramanathan RK, and Von Hoff DD (2013). Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol 4, 2.
50. Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, et al. (2012). Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS One 7, e50586.
51. Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, et al. (2011). Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci USA 108, 12054-12059.